« Home | Calculating U.S. Influenza Deaths » | Senator's HHS Trip for Antibiotic Data Yields Only... » | How Fort Detrick Expansion Threatens Town of Frede... » | MoD ignores ruling on Gulf war syndrome » | Appeals court judge questions biodefense lab plan » | Expert calls for health workers to get flu shots » | Hepatitis, Anthrax Vaccines Found Lying In The Str... » | U.S. Agencies Plan for Mass Deaths » | Federal Rule Waives Informed Consent During Crisis... » | Informed Consent Waived in Public Crisis »

Former HHS secretary named to Emergent board

Washington Business Journal
by Neil Adler, Staff Reporter

A former secretary of the U.S. Department of Health and Human Services has joined the board of directors at Emergent BioSolutions. Gaithersburg-based Emergent BioSolutions, a private biopharmaceutical company, said Wednesday that Louis Sullivan, secretary of the Department of Health and Human Services from 1989 to 1993, was named to its board.


Sullivan, who is also on the board of Silver Spring-based United Therapeutics, currently serves as president emeritus of the Morehouse School of Medicine in Atlanta, where he previously served as president from 1981 to 1989, and again from 1993 to 2002.

He is a director of BioSante Pharmaceuticals, Inhibitex and Henry Schein.

Previously, he served on the boards of some business heavyweights, including Bristol-Myers Squibb, 3M, Georgia Pacific and Cigna.

Sullivan is also a founder and chairman of Medical Education for South African Blacks, a director of the National Center for Addiction and Substance Abuse at Columbia University and a former trustee of the Morehouse School of Medicine and of Africare.

"Dr. Sullivan is a renowned leader in matters of public health and safety both nationally and abroad," says Fuad El-Hibri, chairman and CEO of Emergent, in a statement.

"His academic and medical accomplishments and his distinguished public service have had a global impact on the advancement of health care and our company is very fortunate to have access to his leadership and guidance."

Emergent, thought by many biotech industry observers to be one of then next local drug firms to go public, employs more than 450 people between its facilities in Maryland, Michigan, the United Kingdom, Germany and Singapore. The company's subsidiary, BioPort, makes the only Food and Drug Administration-approved vaccine for anthrax.

Emergent has a handful of other drug and vaccine candidates in clinical and preclinical testing.

Archives